U.S. flag

An official website of the United States government

GRCh37/hg19 22q11.23(chr22:23650872-25002483)x3 AND not provided

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Mar 15, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002473884.1

Allele description [Variation Report for GRCh37/hg19 22q11.23(chr22:23650872-25002483)x3]

GRCh37/hg19 22q11.23(chr22:23650872-25002483)x3

Genes:
  • BCR:BCR activator of RhoGEF and GTPase [Gene - OMIM - HGNC]
  • DDTL:D-dopachrome tautomerase like [Gene - HGNC]
  • DDT:D-dopachrome tautomerase [Gene - OMIM - HGNC]
  • SMARCB1:SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 [Gene - OMIM - HGNC]
  • VPREB3:V-set pre-B cell surrogate light chain 3 [Gene - OMIM - HGNC]
  • ADORA2A:adenosine A2a receptor [Gene - OMIM - HGNC]
  • DRICH1:aspartate rich 1 [Gene - HGNC]
  • UPB1:beta-ureidopropionase 1 [Gene - OMIM - HGNC]
  • CABIN1:calcineurin binding protein 1 [Gene - OMIM - HGNC]
  • C22orf15:chromosome 22 open reading frame 15 [Gene - HGNC]
  • CHCHD10:coiled-coil-helix-coiled-coil-helix domain containing 10 [Gene - OMIM - HGNC]
  • DERL3:derlin 3 [Gene - OMIM - HGNC]
  • GGT1:gamma-glutamyltransferase 1 [Gene - OMIM - HGNC]
  • GGT5:gamma-glutamyltransferase 5 [Gene - OMIM - HGNC]
  • GSTT1:glutathione S-transferase theta 1 [Gene - OMIM - HGNC]
  • GSTT2:glutathione S-transferase theta 2 (gene/pseudogene) [Gene - OMIM - HGNC]
  • GSTT2B:glutathione S-transferase theta 2B [Gene - HGNC]
  • GUCD1:guanylyl cyclase domain containing 1 [Gene - OMIM - HGNC]
  • IGLL1:immunoglobulin lambda like polypeptide 1 [Gene - OMIM - HGNC]
  • LRRC75B:leucine rich repeat containing 75B [Gene - HGNC]
  • MIF:macrophage migration inhibitory factor [Gene - OMIM - HGNC]
  • MMP11:matrix metallopeptidase 11 [Gene - OMIM - HGNC]
  • RGL4:ral guanine nucleotide dissociation stimulator like 4 [Gene - OMIM - HGNC]
  • SNRPD3:small nuclear ribonucleoprotein D3 polypeptide [Gene - OMIM - HGNC]
  • SLC2A11:solute carrier family 2 member 11 [Gene - OMIM - HGNC]
  • SPECC1L:sperm antigen with calponin homology and coiled-coil domains 1 like [Gene - OMIM - HGNC]
  • SUSD2:sushi domain containing 2 [Gene - OMIM - HGNC]
  • ZNF70:zinc finger protein 70 [Gene - OMIM - HGNC]
Variant type:
copy number gain
Cytogenetic location:
22q11.23
Genomic location:
Chr22: 23650872 - 25002483 (on Assembly GRCh37)
Preferred name:
GRCh37/hg19 22q11.23(chr22:23650872-25002483)x3
HGVS:

    Condition(s)

    Synonyms:
    none provided
    Identifiers:
    MedGen: CN517202

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...

    Assertion and evidence details

    Submission AccessionSubmitterReview Status
    (Assertion method)
    Clinical Significance
    (Last evaluated)
    OriginMethodCitations
    SCV002773750Quest Diagnostics Nichols Institute San Juan Capistrano
    criteria provided, single submitter

    (ACMG/ClinGen CNV Guidelines, 2019)
    Likely pathogenic
    (Mar 15, 2022)
    unknownclinical testing

    PubMed (1)
    [See all records that cite this PMID]

    Summary from all submissions

    EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
    not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

    Citations

    PubMed

    Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen).

    Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, Raca G, Ritter DI, South ST, Thorland EC, Pineda-Alvarez D, Aradhya S, Martin CL.

    Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6. Erratum in: Genet Med. 2021 Nov;23(11):2230. doi: 10.1038/s41436-021-01150-9.

    PubMed [citation]
    PMID:
    31690835
    PMCID:
    PMC7313390

    Details of each submission

    From Quest Diagnostics Nichols Institute San Juan Capistrano, SCV002773750.1

    #EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
    1not providednot providednot providednot providedclinical testing PubMed (1)

    Description

    The copy number gain of 22q11.23 involves several protein-coding genes, including SMARCB1 (OMIM 601607) and SPECC1L (OMIM 614140). This copy number gain lies within the recurrent 22q11.2 distal LCR F-H duplication region. Copy number gains within this region have been reported in patients with developmental delay (DD) and other neurocognitive features. This genomic gain is a recurrent 22q11.2 distal LCR F-H duplication region. This type of gain has been reported in patients with developmental delay and other neurocognitive features. In a review of 30 cases, Pinchesfsky et al. reported that common features for duplications in this region include developmental delay (93%), neuropsychiatric features (26%), and nonspecific facial dysmorphisms (74%; Pinchesfsky 2017). In 70% of cases, the distal 22q11.2 duplications were inherited and many, but not all, of the carrier parents were phenotypically normal. Of note, many of the affected individuals had a concomitant variant. There are also reports of patients with overlapping duplications who have achygyria, seizures,hypotonia, impaired growth, esophageal atresia, tracheoesophageal fistula, optic nerve coloboma/dysplasia in optic nerve, and cardiac defects (Coppinger 2009, Nguyen 2017, Puvabanditsin 2015, Tan 2011, Valencia-Pena 2020, Wincent 2010). While there are several copy number gains of this region in the general populations of the Database of Genomic Variants, due to the reduced penetrance associated with this region, a pathogenic role for this copy number variant (CNV) cannot be ruled out. Thus, the clinical significance of this copy number variant (CNV) is likely pathogenic. References: Coppinger et al., Hum Mol Genet. 2009 Apr 15;18(8):1377-83. PMID:19193630Nguyen et al., Clin Case Rep. 2017 Feb 11;5(3):351-356. PMID: 28265405Pinchefsky et al., Child Neurol Open. 2017 Nov 1;4:2329048X17737651.PMID: 29147671Puvabanditsin S, et al., Genet Couns. 2015;26(3):313-20. PMID:26625662Tan et al. Am J Med Genet A. 2011 Jul;155A(7):1623-33., PMID:21671380Valencia-Pena et al., BMC Ophthalmol. 2020 Aug 17;20(1):333. PMID:32807111Wincent et al., Mol Syndromol. 2010;1(5):246-254., PMID: 22140377

    #SampleMethodObservation
    OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
    1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

    Last Updated: Dec 31, 2022